Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC). Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retros...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2021-01, Vol.14, p.1981-1988 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1988 |
|---|---|
| container_issue | |
| container_start_page | 1981 |
| container_title | OncoTargets and therapy |
| container_volume | 14 |
| creator | Furubayashi, Nobuki Negishi, Takahito Sakamoto, Naotaka Shimokawa, Hozumi Morokuma, Futoshi Song, Yoohyun Hori, Yoshifumi Tomoda, Toshihisa Tokuda, Noriaki Seki, Narihito Kuroiwa, Kentaro Nakamura, Motonobu |
| description | To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC).
Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retrospectively analyzed. The objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1.
We analyzed 69 patients (male, n=51; median age, 71 years) with 226 metastases. The ORR was 23.2%. In total, 32, 31, 16, 14, 13 and 7 patients had measurable lung (OSSR 31.3%), lymph node (OSSR 29.0%), local recurrence (OSSR 12.5%), primary tumor organ (OSSR 7.1%), liver (OSSR 23.1%) and bone (OSSR 28.6%) disease, respectively. The median overall survival (OS) for pembrolizumab was 10.9 months (95% confidence interval, 5.9‑13.7 months). Regarding organ-specific OS, a Log rank test significant differences in OS were confirmed between patients with and without primary tumor organ disease (p=0.046) and liver metastasis (p |
| doi_str_mv | 10.2147/OTT.S299724 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669417981</galeid><sourcerecordid>A669417981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-e56759c874133b195345e8ebfe7a02b03d740f1fe1ba226bd615cfd6ad1979913</originalsourceid><addsrcrecordid>eNptkk1r3DAQhk1paT7aU-_FUCiB4q1kyZJ1KWyXfkFgQ7M5C1kerxVkyZHsQPrrqyXbdLcUHSQ0z7yjGb1Z9gajRYkp_7jebBbXpRC8pM-yU4x5XTBB0POD80l2FuMtQozVJX2ZnRDCOaOUn2Z367BVrrgeQZvO6HwzDz7kPyGO3kXIJ59fwdAEb82veVBNbly-bO-V09DmN8FPPVijbL5SQRvnB5UvuwlCfmXVZNw8FJ9VTOSqh2HHBjU-vMpedMpGeL3fz7Obr182q-_F5frbj9XystAVFVMBFeOV0DWnmJAGi4rQCmpoOuAKlQ0iLaeowx3gRpUla1qGK921TLVYcCEwOc8-PeqOczNAq8FNQVk5BjOo8CC9MvI44kwvt_5eclFzglgSuNgLBH83Q5zkYKIGa5UDP0dZVohVmCJSJvTdP-itn4NL7SUKk6pmNRd_qa2yII3rfKqrd6JyyZigOFXevXvxHyqtFgajvYPOpPujhPcHCT0oO_XR23ky6QuPwQ-PoA4-xgDd0zAwkjsryWQlubdSot8ezu-J_eMd8hsK_MN3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2513586879</pqid></control><display><type>article</type><title>Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy</title><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Furubayashi, Nobuki ; Negishi, Takahito ; Sakamoto, Naotaka ; Shimokawa, Hozumi ; Morokuma, Futoshi ; Song, Yoohyun ; Hori, Yoshifumi ; Tomoda, Toshihisa ; Tokuda, Noriaki ; Seki, Narihito ; Kuroiwa, Kentaro ; Nakamura, Motonobu</creator><creatorcontrib>Furubayashi, Nobuki ; Negishi, Takahito ; Sakamoto, Naotaka ; Shimokawa, Hozumi ; Morokuma, Futoshi ; Song, Yoohyun ; Hori, Yoshifumi ; Tomoda, Toshihisa ; Tokuda, Noriaki ; Seki, Narihito ; Kuroiwa, Kentaro ; Nakamura, Motonobu</creatorcontrib><description>To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC).
Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retrospectively analyzed. The objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1.
We analyzed 69 patients (male, n=51; median age, 71 years) with 226 metastases. The ORR was 23.2%. In total, 32, 31, 16, 14, 13 and 7 patients had measurable lung (OSSR 31.3%), lymph node (OSSR 29.0%), local recurrence (OSSR 12.5%), primary tumor organ (OSSR 7.1%), liver (OSSR 23.1%) and bone (OSSR 28.6%) disease, respectively. The median overall survival (OS) for pembrolizumab was 10.9 months (95% confidence interval, 5.9‑13.7 months). Regarding organ-specific OS, a Log rank test significant differences in OS were confirmed between patients with and without primary tumor organ disease (p=0.046) and liver metastasis (p<0.001).
Metastases and primary tumor organ disease showed different tumor responses to pembrolizumab. The most prominent tumor response was found in lung metastasis and the least response was found in primary organ sites. The mechanisms of these different responses were unclear and there does not appear to be a constant trend between tumor shrinkage and OS in tumor sites. Further studies are needed.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S299724</identifier><identifier>PMID: 33776447</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Atrophy ; Bladder ; Bladder cancer ; Cancer ; Carcinoma ; Chemotherapy ; Disease control ; Health aspects ; Immunotherapy ; Liver ; Lymph nodes ; Lymphatic system ; Melanoma ; Metastases ; Metastasis ; Monoclonal antibodies ; Original Research ; Patients ; Pembrolizumab ; Platinum ; Response rates ; Solid tumors ; Targeted cancer therapy ; Urothelial carcinoma</subject><ispartof>OncoTargets and therapy, 2021-01, Vol.14, p.1981-1988</ispartof><rights>2021 Furubayashi et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Furubayashi et al. 2021 Furubayashi et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-e56759c874133b195345e8ebfe7a02b03d740f1fe1ba226bd615cfd6ad1979913</citedby><cites>FETCH-LOGICAL-c549t-e56759c874133b195345e8ebfe7a02b03d740f1fe1ba226bd615cfd6ad1979913</cites><orcidid>0000-0002-9346-1900 ; 0000-0002-3798-8644 ; 0000-0001-9159-493X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987306/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987306/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33776447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furubayashi, Nobuki</creatorcontrib><creatorcontrib>Negishi, Takahito</creatorcontrib><creatorcontrib>Sakamoto, Naotaka</creatorcontrib><creatorcontrib>Shimokawa, Hozumi</creatorcontrib><creatorcontrib>Morokuma, Futoshi</creatorcontrib><creatorcontrib>Song, Yoohyun</creatorcontrib><creatorcontrib>Hori, Yoshifumi</creatorcontrib><creatorcontrib>Tomoda, Toshihisa</creatorcontrib><creatorcontrib>Tokuda, Noriaki</creatorcontrib><creatorcontrib>Seki, Narihito</creatorcontrib><creatorcontrib>Kuroiwa, Kentaro</creatorcontrib><creatorcontrib>Nakamura, Motonobu</creatorcontrib><title>Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC).
Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retrospectively analyzed. The objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1.
We analyzed 69 patients (male, n=51; median age, 71 years) with 226 metastases. The ORR was 23.2%. In total, 32, 31, 16, 14, 13 and 7 patients had measurable lung (OSSR 31.3%), lymph node (OSSR 29.0%), local recurrence (OSSR 12.5%), primary tumor organ (OSSR 7.1%), liver (OSSR 23.1%) and bone (OSSR 28.6%) disease, respectively. The median overall survival (OS) for pembrolizumab was 10.9 months (95% confidence interval, 5.9‑13.7 months). Regarding organ-specific OS, a Log rank test significant differences in OS were confirmed between patients with and without primary tumor organ disease (p=0.046) and liver metastasis (p<0.001).
Metastases and primary tumor organ disease showed different tumor responses to pembrolizumab. The most prominent tumor response was found in lung metastasis and the least response was found in primary organ sites. The mechanisms of these different responses were unclear and there does not appear to be a constant trend between tumor shrinkage and OS in tumor sites. Further studies are needed.</description><subject>Atrophy</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Carcinoma</subject><subject>Chemotherapy</subject><subject>Disease control</subject><subject>Health aspects</subject><subject>Immunotherapy</subject><subject>Liver</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Original Research</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Platinum</subject><subject>Response rates</subject><subject>Solid tumors</subject><subject>Targeted cancer therapy</subject><subject>Urothelial carcinoma</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1r3DAQhk1paT7aU-_FUCiB4q1kyZJ1KWyXfkFgQ7M5C1kerxVkyZHsQPrrqyXbdLcUHSQ0z7yjGb1Z9gajRYkp_7jebBbXpRC8pM-yU4x5XTBB0POD80l2FuMtQozVJX2ZnRDCOaOUn2Z367BVrrgeQZvO6HwzDz7kPyGO3kXIJ59fwdAEb82veVBNbly-bO-V09DmN8FPPVijbL5SQRvnB5UvuwlCfmXVZNw8FJ9VTOSqh2HHBjU-vMpedMpGeL3fz7Obr182q-_F5frbj9XystAVFVMBFeOV0DWnmJAGi4rQCmpoOuAKlQ0iLaeowx3gRpUla1qGK921TLVYcCEwOc8-PeqOczNAq8FNQVk5BjOo8CC9MvI44kwvt_5eclFzglgSuNgLBH83Q5zkYKIGa5UDP0dZVohVmCJSJvTdP-itn4NL7SUKk6pmNRd_qa2yII3rfKqrd6JyyZigOFXevXvxHyqtFgajvYPOpPujhPcHCT0oO_XR23ky6QuPwQ-PoA4-xgDd0zAwkjsryWQlubdSot8ezu-J_eMd8hsK_MN3</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Furubayashi, Nobuki</creator><creator>Negishi, Takahito</creator><creator>Sakamoto, Naotaka</creator><creator>Shimokawa, Hozumi</creator><creator>Morokuma, Futoshi</creator><creator>Song, Yoohyun</creator><creator>Hori, Yoshifumi</creator><creator>Tomoda, Toshihisa</creator><creator>Tokuda, Noriaki</creator><creator>Seki, Narihito</creator><creator>Kuroiwa, Kentaro</creator><creator>Nakamura, Motonobu</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9346-1900</orcidid><orcidid>https://orcid.org/0000-0002-3798-8644</orcidid><orcidid>https://orcid.org/0000-0001-9159-493X</orcidid></search><sort><creationdate>20210101</creationdate><title>Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy</title><author>Furubayashi, Nobuki ; Negishi, Takahito ; Sakamoto, Naotaka ; Shimokawa, Hozumi ; Morokuma, Futoshi ; Song, Yoohyun ; Hori, Yoshifumi ; Tomoda, Toshihisa ; Tokuda, Noriaki ; Seki, Narihito ; Kuroiwa, Kentaro ; Nakamura, Motonobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-e56759c874133b195345e8ebfe7a02b03d740f1fe1ba226bd615cfd6ad1979913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Atrophy</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Carcinoma</topic><topic>Chemotherapy</topic><topic>Disease control</topic><topic>Health aspects</topic><topic>Immunotherapy</topic><topic>Liver</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Original Research</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Platinum</topic><topic>Response rates</topic><topic>Solid tumors</topic><topic>Targeted cancer therapy</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furubayashi, Nobuki</creatorcontrib><creatorcontrib>Negishi, Takahito</creatorcontrib><creatorcontrib>Sakamoto, Naotaka</creatorcontrib><creatorcontrib>Shimokawa, Hozumi</creatorcontrib><creatorcontrib>Morokuma, Futoshi</creatorcontrib><creatorcontrib>Song, Yoohyun</creatorcontrib><creatorcontrib>Hori, Yoshifumi</creatorcontrib><creatorcontrib>Tomoda, Toshihisa</creatorcontrib><creatorcontrib>Tokuda, Noriaki</creatorcontrib><creatorcontrib>Seki, Narihito</creatorcontrib><creatorcontrib>Kuroiwa, Kentaro</creatorcontrib><creatorcontrib>Nakamura, Motonobu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furubayashi, Nobuki</au><au>Negishi, Takahito</au><au>Sakamoto, Naotaka</au><au>Shimokawa, Hozumi</au><au>Morokuma, Futoshi</au><au>Song, Yoohyun</au><au>Hori, Yoshifumi</au><au>Tomoda, Toshihisa</au><au>Tokuda, Noriaki</au><au>Seki, Narihito</au><au>Kuroiwa, Kentaro</au><au>Nakamura, Motonobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>1981</spage><epage>1988</epage><pages>1981-1988</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>To evaluate the organ-specific therapeutic effect of pembrolizumab after the failure of platinum-based chemotherapy for advanced urothelial carcinoma (UC).
Patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy and who had measurable disease were retrospectively analyzed. The objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1.
We analyzed 69 patients (male, n=51; median age, 71 years) with 226 metastases. The ORR was 23.2%. In total, 32, 31, 16, 14, 13 and 7 patients had measurable lung (OSSR 31.3%), lymph node (OSSR 29.0%), local recurrence (OSSR 12.5%), primary tumor organ (OSSR 7.1%), liver (OSSR 23.1%) and bone (OSSR 28.6%) disease, respectively. The median overall survival (OS) for pembrolizumab was 10.9 months (95% confidence interval, 5.9‑13.7 months). Regarding organ-specific OS, a Log rank test significant differences in OS were confirmed between patients with and without primary tumor organ disease (p=0.046) and liver metastasis (p<0.001).
Metastases and primary tumor organ disease showed different tumor responses to pembrolizumab. The most prominent tumor response was found in lung metastasis and the least response was found in primary organ sites. The mechanisms of these different responses were unclear and there does not appear to be a constant trend between tumor shrinkage and OS in tumor sites. Further studies are needed.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>33776447</pmid><doi>10.2147/OTT.S299724</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9346-1900</orcidid><orcidid>https://orcid.org/0000-0002-3798-8644</orcidid><orcidid>https://orcid.org/0000-0001-9159-493X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2021-01, Vol.14, p.1981-1988 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987306 |
| source | Dove Press Free; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Atrophy Bladder Bladder cancer Cancer Carcinoma Chemotherapy Disease control Health aspects Immunotherapy Liver Lymph nodes Lymphatic system Melanoma Metastases Metastasis Monoclonal antibodies Original Research Patients Pembrolizumab Platinum Response rates Solid tumors Targeted cancer therapy Urothelial carcinoma |
| title | Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A48%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Organ-Specific%20Tumor%20Response%20to%20Pembrolizumab%20in%20Advanced%20Urothelial%20Carcinoma%20After%20Platinum-Based%20Chemotherapy&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Furubayashi,%20Nobuki&rft.date=2021-01-01&rft.volume=14&rft.spage=1981&rft.epage=1988&rft.pages=1981-1988&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S299724&rft_dat=%3Cgale_pubme%3EA669417981%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2513586879&rft_id=info:pmid/33776447&rft_galeid=A669417981&rfr_iscdi=true |